Entera Bio Ltd. (ENTX)
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
📈 **POSITIVE** • Low confidence analysis (59%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (78%) **Content type:** Clinical